Genomma Lab Intl Sab Ord (GNMLF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for joining Genoma Lab's first quarter 2025 earnings conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. As a reminder, this meeting is being recorded and will be available for replay on the investor relations section of Genoma's website following the call. I'll now turn the call over to Christian Ibañez, Genoma's Head of Investor Relations. Please, go ahead. Thank you and welcome, everyone. On today's call are Marcos Barbieri, Chief Executive Officer, and Antonio Zamora, Chief Financial Officer. Before we get started, I'd like to remind you that the remarks today will include forward-looking statements. such as the company's financial guidance and expectations, including long-term objectives and forecasts, as well as expectations regarding Denoma's business, assets, products, strategies, demand, and markets. These statements are subject to risks and uncertainties that could cause actual results to differ materially. They are also based on assumptions as of today, and the company undertakes no obligation to update them as a result of new information or future events. Let me now turn the call over to Mr. Marcos Barbieri. Good morning, everyone, and thank you, Chris. I would like to open the call by announcing we have identified 10 targeted projects where we will invest excess cash and profits to accelerate sales growth. We are confident that the successful execution of our growth projects will drive low team sales growth over the mid-term, while maintaining an average of 24% EBITDA margin. As part of our growth strategy, we have identified a set of focused initiatives across key categories and capabilities where we believe targeted investment can unloc...